Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

Checkpoint inhibitors targeting the PD-1/PD-L1 axis are promising immunotherapies shown to elicit objective responses against multiple tumor types, yet these agents fail to benefit most patients with carcinomas. This highlights the need to develop effective therapeutic strategies to increase respons...

Full description

Bibliographic Details
Main Authors: Kristin C. Hicks, Massimo Fantini, Renee N. Donahue, Angie Schwab, Karin M. Knudson, Sarah R. Tritsch, Caroline Jochems, Paul E. Clavijo, Clint T. Allen, James W. Hodge, Kwong Y. Tsang, Jeffrey Schlom, Sofia R. Gameiro
Format: Article
Language:English
Published: Taylor & Francis Group 2018-11-01
Series:OncoImmunology
Subjects:
histone deacetylase
hdac
avelumab
adcc
solid carcinoma
vorinostat
entinostat
nk cell function
checkpoint inhibitor
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1466018

Internet

http://dx.doi.org/10.1080/2162402X.2018.1466018

Similar Items